Evaluation of pharmacokinetic parameters and dipeptidyl peptidase‐4 inhibition following single doses of sitagliptin in healthy, young Japanese males

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Sitagliptin is an oral antihyperglycaemic agent that improves glycaemic control by inhibiting dipeptidyl peptidase‐4 (DPP‐4), the enzyme that is principally responsible for inactivation of incretins. Incretins are endogenous peptide hormones that support gl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2011-03, Vol.71 (3), p.429-436
Hauptverfasser:	Herman, Gary A., Mistry, Goutam C., Yi, Bingming, Bergman, Arthur J., Wang, Amy Q., Zeng, Wei, Chen, Li, Snyder, Karen, Ruckle, Jon L., Larson, Patrick J., Davies, Michael J., Langdon, Ronald B., Gottesdiener, Keith M., Wagner, John A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Asian Continental Ancestry Group Biological and medical sciences Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - administration & dosage Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dose-Response Relationship, Drug Double-Blind Method DPP‐4 inhibitor Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Male Medical sciences Middle Aged MK‐0431 Pharmacokinetic Dynamic Relationships Pharmacology. Drug treatments Pyrazines - administration & dosage Pyrazines - adverse effects race Research Design Sitagliptin Phosphate Statistics as Topic Triazoles - administration & dosage Triazoles - adverse effects Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!